Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET

Company Participants

Jim Caruso – President and Chief Executive Officer
Andrei Shustov – Senior Vice President-Medical
Jarrod Longcor – Chief Operating Officer
Shane Lea – Chief Commercial Officer
Chad Kolean – Chief Financial Officer

Conference Call Participants

Jonathan Aschoff – ROTH
Jeff Jones – Oppenheimer
Ted Tenthoff – Piper Sandler

Operator

Good morning, and welcome to Cellectar Biosciences Second Quarter 2024 Financial Results Call. Today’s call is being recorded. Before we begin, I would like to remind everyone that statements made during this call relating to Cellectar’s expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties that could differ materially from those forecast due to the impact of many factors beyond the control of Cellectar. The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events or otherwise.

Participants are directed to the cautionary notes set forth in today’s press release which is available on the Investor Relations portion of the company’s website as well as the risk factors set forth in Cellectar’s annual reports filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements.

At this time, I would like to turn the call over to Jim Caruso, President and Chief Executive Officer of Cellectar. Mr. Caruso, please go ahead.

Jim Caruso

Thank you, operator, and good morning, everyone. It is my pleasure to be here with you to provide a corporate update for our second quarter of 2024. With me today are Dr. Andrei Shustov, Senior Vice President, Medical; Jarrod Longcor, Chief Operating Officer; Shane Lea, Chief Commercial Officer; and Chad Kolean, Chief Financial Officer.

I will begin today with a brief recap of our progress over the past quarter and discuss anticipated near-term milestones.

I will then ask Chad to provide an update on our financials. Andrei will follow with additional insights regarding our CLOVER-WaM pivotal study, followed by Jarrod, who will provide an operations update on the regulatory front and manufacturing. Finally, Shane will review our commercial progress. We will then open the call for Q&A.